Vancouver, Canada – Virogin Biotech (“Virogin”) is pleased to announce it has recently signed an agreement with China National Biotec Group (CNBG) to create a Joint Venture that will focus on the research & development, clinical development, and commercialization of oncolytic virotherapies.
Vancouver, Canada – Virogin Biotech Ltd. (“Virogin”) is pleased to announce the completion of its Series A+ round of financing for a total of $5 million USD on February 28th, 2017.
Vancouver, Canada – Virogin Biotech Ltd. (“Virogin”) is pleased to announce its strategic collaboration with Guangdong University of Technology (GDUT) in China.
Vancouver, Canada – Virogin Biotech Ltd. (“Virogin”) is pleased to announce that it has received approval for National Research Council-Industrial Research Assistance Program (NRC-IRAP) funding on April 22nd, 2016.
Shanghai, China - Virogin Biotech Ltd ("Virogin") is pleased to announce the completion of A-round common share financing for a total of $7 million USD on March 16th, 2016.
Even though the study of immunotherapy has been around for more than a century, its value to the treatment of cancer is greater today than ever. Drug development is progressing rapidly, data from clinical trials continues to impress, and, most important, more and more patients are experiencing remarkable responses to these treatments that allow them to lead longer, healthier lives.
Vancouver, Canada - Virogin Biotech Ltd. ("Virogin"), an early stage biotech research company, is proud to announce a collaboration agreement with Johnson & Johnson Innovation and Janssen Biotech, Inc. (“Janssen”) to further the development of Virogin’s novel oncolytic therapeutics for the treatment of cancer.